Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:
Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00) Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35) Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21) Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10) Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33) Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38) Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08) Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56) Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48) Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18) Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56) CME information and select publications

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O’Reilly, including the following topics.
Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O’Reilly (31:46) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics.
Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00) HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler (25:17) CME information and select publications

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics.
Introduction (0:00) Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30) Biliary Tract Cancers (BTCs) — Dr Finn (33:16) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics.
Current and Potential Role of Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancers — Dr Klempner (0:00) Other Available and Emerging Therapeutic Approaches — Dr Janjigian (31:42) CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics.
Introduction (0:00) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates in Multiple Myeloma (MM) — Dr Callander (8:25) Integration of Other Novel Therapies into the Management of Newly Diagnosed and Relapsed/Refractory MM — Dr Richardson (31:52) CME information and select publications